Peptide name : B5

Source/Organism : Analogue of BP 100

Linear/Cyclic : Linear

Chirality : L

Peptide length: 13

C-terminal modification: Linear

N-terminal modification : Amidation

Non-natural peptide information:

Assay type : MTT assay

Assay time : 48-h

Activity : IC50 = 28.3 ± 2.3 μM

Cell line : K-562/ADM

Cancer type : Leukemia Cancer

Other activity : Antimicrobial

Amino acid composition bar chart :

Molecular mass : 1663.1841 Dalton

Aliphatic index : 1.5

Instability index : -20.169

Hydrophobicity (GRAVY) : -0.169

Isoelectric point : 10.398

Charge (pH 7) : 5.7531

Aromaticity : 15.38

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 0.8571

hydrophobic moment : 2.4006

Missing amino acid : A,C,D,E,G,H,M,N,P,Q,R,S,T,V,W

Most occurring amino acid : K

Most occurring amino acid frequency : 6

Least occurring amino acid : F

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (76., 0, 53.)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O

1 : Zhang B, et al. Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities. Chem Biol Drug Des. 2017; 90:972-980. doi: 10.1111/cbdd.13023

Paper title : Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities.

Doi : https://doi.org/10.1111/cbdd.13023

Abstract : Tumor chemotherapy, which plays an important role in the clinical treatment of metastatic cancer, is limited by low selectivity and drug resistance in clinical application. In our study, we selected antimicrobial peptide BP100 as a lead peptide, designed, and synthesized a series of novel antineoplastic peptides through solid-phase synthesis. Among them, B4 and B8 showed excellent anticancer activity. As revealed by further investigations, these peptides could disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis. In addition, they also showed multidrug resistance-reversing effects by performing effective antitumor activity against multidrug-resistant cells. As a result, these peptides may possibly be regarded as a promising candidate for cancer treatment.